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Introduction
PANC1 cells FAC did not induced expression of EMT markers, but it resulted in a 2.7-fold 182 decrease in expression of CDH1. Moreover, iron chelation decreased the expression of EMT 183 markers (ZEB1, SNAI1 and TWIST) in both BXPC3 and PANC-1 (Figure 3 -figure supplement   184   1A, B) . Interestingly, DFO also decreased CDH1 expression in PANC-1. These data suggest that 185 iron chelation could inhibit iron-dependent EMT of cancer cells and might be dependent on the 186 Kras mutations status of cells. To further assess how the iron-dependent EMT modulation 187 regulates the invasive potential of BXPC3 and PANC-1, we measured invasion via transwell 188 assay with a BME coated membrane. We showed that iron treatments significantly increased the 193 Iron regulates NDRG1 expression which is inversely correlated with LCN2 expression in 194 PDAC. 195 Iron is known to downregulate the expression of the iron related metastasis suppressor, 196 N-myc downstream regulated gene 1 (NDRG1), and this downregulation is associated with 197 increased proliferation and invasion of PDAC (34, 41, 42) . Therefore, we measured the 198 expression of NDRG1 after treating BXPC3 and PANC-1 cells with 150μM and 20mM FAC. 199 We showed that NDRG1 expression decreases 33-fold in BXPC3 and 22-fold in PANC-1 cells 200 after FAC treatment ( Figure 4A ). NDRG1 expression was considerably higher in BXPC3 201 compared to PANC-1 cells not treated with FAC. Moreover, iron chelation induced the 202 expression of NDRG1 in both BXPC3 and PANC-1 cells (Figure 4B) . Our data suggests that 203 iron chelation could decrease iron-induced metastasis via EMT and NDRG1 regulation. NDRG1 expression is involved in cell line differentiation, with well differentiated PDAC 205 cells expressing higher levels of NDRG1 and poorly differentiated PDAC cells expressing lower 206 levels or no NDRG1 mRNA (35) . Moreover, NDRG1 expression was found to be negatively 207 regulated by LCN2 in cholangiocarcinoma cells (43) . Therefore, we assessed the expression of 208 LCN2 and NDRG1 in multiple human PDAC cell lines and a HPSC cell line compared to a 209 normal human pancreatic ductal epithelial cell line (HPDE) . We showed that in general there 210 was an inverse relationship between NDRG1 expression and LCN2 expression, except for 211 PANC-1 and MIAPACA2, where both NDRG1 and LCN2 expression were low (Figure 4C and 212 4E). Since these genes are involved in iron regulation, we also assessed the expression of the 213 iron transport gene FTH1 and showed that all cell lines had significantly lower expression levels 214 than HPDE. (Figure 3 -figure supplement 1C) . To validate our findings in another model, we 215 examined Ndrg1 and Lcn2 expression levels in the pancreatic tissue of a genetically engineered 216 mouse model of diet-induced PDAC (KRAS G12D /CRE) (5, 44) . We showed that Lcn2 expression 217 was increased and Ndrg1 expression was decreased in KRAS G12D /CRE mice, compared to the 218 CRE control mice ( Figure 4D-4F ).
219
Lcn2 depletion elevates Ndrg1 expression, which is regulated in an iron-dependent manner. 220 To further understand the role of LCN2 expression and iron levels in modulating NDRG1 221 expression in PDAC, we generated a KPC cell line with a biallelic Lcn2 deletion. Several Lcn2 -/-222 (KO) clones were isolated and characterized by a series of genomic PCR assays, and two of 223 those Lcn2 KO clones were used in this study ( Figure 5 -figure supplement 1) . Quantitative 
232
To investigate whether the lack of Lcn2 expression modulates the levels of Ndrg1 233 expression in cancer cells treated with iron, KPC-parental cells, Lcn2-KO clone 1 and Lcn2-KO 234 clone 2 were treated with various concentrations of FAC and changes in Ndrg1 gene expression 235 were examined ( Figure 5A ). We showed that Ndrg1 expression was elevated 2.5 to 3.3-fold in of Ndrg1, which was regulated by iron levels. To further understand this relationship, we 242 measured Lcn2 expression in the KPC-parental clone cells and found an overall increased in 243 Lcn2 expression at increasing doses of FAC ( Figure 5) . These data suggest that iron levels 244 regulate expression of Lcn2 in cancer cells.
245
To verify iron influx into the cells, the expression of Fth1 was quantified. Fth1 246 expression was overall increased with increasing iron concentrations in all cells regardless of 247 Lcn2 expression ( Figure 5E ). These results indicate that iron was being taken by the cells and 248 stored even in the absence of Lcn2 expression.
To assess whether iron chelation had the inverse effects of iron treatments on KPC cells 250 with or without Lcn2 expression, we treated the cell lines with a range of DFO concentrations 251 and measured the expression of Ndrg1. In the KPC-parental cells, increasing concentrations of 252 DFO increased Ndrg1 expression ( Figure 5B) . However, the Lcn2-KO clones exhibited an 253 overall decrease in Ndrg1 expression. Furthermore, we measured Lcn2 and Fth1 expression after 254 DFO treatments and showed that DFO increased Lcn2 expression at high concentrations in the 255 KPC-parental cell line ( Figure 5D ) and decreased Fth1 expression overall in all KPC cell lines 256 regardless of Lcn2 expression ( Figure 5F ). These results further depict the complexity of iron 257 regulation and its association with other factors in PDAC. A plausible explanation for these 258 results is that in a low iron environment, KPC cells decrease the expression of the iron storage 259 gene Fth1 because iron needs to be released from storage to be utilized by the cell, while 260 increasing Lcn2 expression in order to scavenge for iron and compensate for the lack of iron 261 available in the cell.
262
Lcn2 depletion regulates the expression of genes involved in extracellular matrix deposition 263 and cell migration pathways 264 To further understand other pathways that are regulated by the lack of Lcn2 expression in 265 PDAC cells, we performed RNA sequencing analysis of the KPC parental and Lcn2-KO clone 266 cell lines. A heat map of the hierarchal clustering of genes in KPC parental and Lcn2-KO clones 267 shows that the clustering of genes differed greatly between the KPC parental and the Lcn2-KO 268 clones, while the clustering of genes between both Lcn2-KO clones were similar to each other 269 ( Figure 6A ). 270 Gene Ontology (GO) analyses were performed to identify the processes in which 271 differentially expressed genes of these cell lines were involved. These results showed that Lcn2 Since iron is essential for cell growth, DNA synthesis, and apoptosis, tumor cells tend to 287 have elevated iron requirements relative to normal somatic cells due to their increased 288 proliferation rates (47). In this study, the human PDAC cell line BXPC3, increased proliferation 289 in response to changes in iron concentration compared to PANC-1 cells (Figure 1 ). BXPC3 cells 290 express an un-mutated KRAS gene while PANC-1 express a mutant KRAS G12D (37, 48, 49), 291 possibly accounting for the differences observed in these cell lines. These effects are slightly 292 reversed when iron is chelated with DFO. Interestingly, in PDAC patients in which Kras is not 293 mutated, iron concentrations are significantly higher (50). This suggests that Kras mutation status 294 could be involved in iron homeostasis in the same way that the TP53 mutation, another common mutation in PDAC patients, was found to regulate cellular iron transport and storage (51).
296
Moreover, triapine, an iron chelator and an inhibitor of the M2 subunit of the ribonucleotide 297 reductase, has been used to improve radiation therapy outcomes in PDAC patients (52). In 298 addition, iron chelation has also been effective in reducing tumor growth alone or in combination 299 with other treatments in vitro and in PDAC xenograft models (53) (54) (55) (56) .
300
Considering the interaction of iron with the pro-inflammatory cytokine LCN2, we sought 301 to understand whether iron contributed to the inflammatory responses observed in PDAC. Here 302 we showed that iron induced inflammation by increasing the expression of IL6 and IL1β in both 303 PDAC cancer and pancreatic stellate cells. However, the expression of the LCN2 receptor 304 SLC22A17 remained unchanged (Figure 2 A, C, G) . In breast cancer, iron contributes to 305 chemoresistance by increasing IL6 production in tumor associated macrophages (57).
306
Chemoresistance is one of the most common features in PDAC in part due to the dense stromal 307 environment (58). For this reason, additional studies should investigate whether iron modulation 308 could be used in combination with current therapies to decrease chemoresistance in PDAC.
309
Iron concentrations are associated with EMT in tumors cells (10, 11) . The crucial steps of 310 EMT leading to metastasis are characterized by a decrease in intercellular adhesion of the tumor 311 cells, a loss of epithelial morphology, and increased invasion, a hallmark of mesenchymal 312 morphology (27, 59) . At the molecular and transcriptional level, EMT is characterized by 313 promoting the degradation of basement membranes and ECM, leading to invasion and metastasis 314 (46). Here we showed that excess iron in the media of BXPC3 cells increased the expression of (35, 37, 48) . Previous reports suggest that Ras expression can modulate cellular processes such 320 as cell survival in ovarian cancer (36) and other factors in PDAC (50, 60) . Iron chelation has 321 been effective at suppressing EMT in lung, prostate, colon and esophageal cancer (20-23).
322
However, a study in mice showed that while EMT induces chemoresistance in PDAC, EMT is 323 not needed to develop an invasive and metastatic phenotype (61). Contributing to the Kras 324 expression difference among the cell lines, we found higher LCN2 expression in BXPC3 cells 325 compared to the mutant KRAS PANC-1 cells ( Figure 4C ), which might support the differences 326 in iron responses and iron-dependent EMT initiation between the lines. Future studies aimed at 327 understanding whether LCN2 expression is associated with Kras mutations in PDAC are 328 necessary to determine whether LCN2 and iron targeted therapy will benefit PDAC patients.
329
Besides inducing EMT, iron also regulates expression of the metastatic suppressor 330 NDRG1 (21, 23, 34). NDRG1 expression can be regulated by other effectors including N-myc, 331 acetylation of histones, hypoxia, and intracellular calcium levels (21, 34, 41, 42, 62, 63) . NDRG1 332 is responsible for the suppression of glycolytic metabolism in PDAC, a metabolic pathway 333 utilized by many cancers for growth (60). In our study, we found that increased levels of iron 334 downregulated the expression of NDRG1, while iron chelation upregulated NDRG1 expression in 335 PDAC cancer cells. Moreover, baseline expression of NDRG1 was lower in the PANC-1 cell line 336 compared to the BXPC3 cell line (Figure 4A, B) . Similar results were observed in the mouse 337 pancreatic cancer cell line, where the induction of oncogenic Kras G12D mutation decreased 338 significantly the protein levels of NDRG1 (60). Since NDRG1 expression is already reduced in 339 the mutant Kras compared to wild type Kras cell line, the further decrease in NDRG1 expression 340 caused by iron might not have the same impact on promoting EMT. Although Kras mutations and elevated expression of LCN2 are common in PDAC, our data suggests that knowing the 342 mutation status of Kras and LCN2 levels in patients could help inform whether iron modulation 343 and LCN2 blockade could serve as a novel treatment approach.
344
Intracellular iron is regulated by the expression of FTH1, which functions as an iron 345 storage protein and controls intracellular iron release (64). Here we showed that FTH1 346 expression is lower in PDAC cell lines compared to a normal human pancreatic ductal epithelial 347 cell line (Figure 3 -figure supplement 1) . These data suggest that there is an increase of free 348 iron and possible reduction in iron storage due to the high demand for iron by PDAC cells. FTH1 349 expression is also downregulated in HPSC, potentially for the same reason. Lower amounts of 350 intracellular FTH1 result in higher concentrations of free iron, contributing to elevated reactive 351 oxygen species production, another essential factor in EMT (26). In human breast and lung 352 cancer cell lines, inhibition of FTH1 expression promoted migration, decreased adhesion, and 353 displayed a fibroblastoid morphology that lead to EMT (19) . These findings support the 354 observation that increased extracellular and intracellular iron, as well as reduced intracellular 355 FTH1, results in EMT.
356
To further understand how LCN2 expression in cancer cells modulated iron responses,
357
LCN2 expression was deleted via CRISPR. RNA sequencing was used to identify other 358 processes regulated by Lcn2 expression in PDAC. We showed that Lcn2 deletion is associated 359 with differentially expressed genes involved in extracellular matrix related pathways and 360 processes vital to cancer progression, such as cell migration, cell motility, and collagen binding 361 (Figure 6 B, C, D) . These results validate and build upon our prior work supporting the finding 362 that stromal cells treated with LCN2 increase inflammation in the TME of PDAC and that lack 363 of Lcn2 expression in mice delays PDAC tumor formation and increases survival (5). In particular, the processes of cell adhesion, proteinaceous extracellular matrix, and integrin 365 pathway were strongly over-represented in the tumor cells that lack Lcn2 expression ( Figure 7) . 366 Cell adhesion is associated with an epithelial phenotype and it is known to be reduced during 367 EMT and metastasis (27) . Moreover, the proteinaceous extracellular matrix and integrin 368 pathways are tightly associated with the organization of the extracellular matrix in cancer 369 progression (65).
370
Overall, in our study we demonstrated that iron promotes inflammation, invasion, and 371 EMT on PDAC cell lines partially by modulating NDRG1 expression. Iron responses were 372 strongly associated with LCN2 expression, which contributes to the formation and function of 373 the TME. Finally, our data suggests that iron chelation can potentially decrease invasion and 374 metastasis in PDAC, especially if combined with an LCN2 blockade. Additional studies are 375 needed to assess the therapeutic potential of LCN2 blockade and iron modulation on PDAC 376 progression and metastasis, and its correlation with Kras mutations status. Our study also 377 suggests that Kras mutations may play a role in how cancer cells respond to iron in PDAC.
378
Therefore, knowing the mutation status of KRAS in PDAC would help determine whether a 379 patient could benefit from iron chelation therapy and LCN2 blockade in conjunction with current 380 treatment standards of care.
381

Materials and Methods
382
Cell culture and cell lines 383 Cell lines were cultured at 37 o C with 5% CO2 in DMEM supplemented with 4.5 g/l 384 glucose, L-glutamine and 10% FBS. All cell lines tested negative for the presence of Trp53 -/-, PDX-1-CRE, (KPC) genetically engineered mouse, as described in (5, 68) . The KPC 391 cell line was subcloned to derive a single clone for CRISPR cloning. HPSC were acquired from a 392 resected human PDAC sample as described in (5). 
RNAseq data processing and analysis
Sequencing reads were aligned to mouse reference genome GRCm38 with hisat2 (74).
474
Gene expression was quantified with featureCounts software (75) for genes annotated by 475 ensembl Mus_musculus.GRCm38.83, counting the primary alignment in the case of 476 multimapped reads. Genes were included if at least half of the samples had an expression of 2 477 CPM. Raw counts were normalized by voom and differential expression was performed with 478 limma (76).
479
For the heatmap, we selected genes with logFC > 1 or <-1 and with FDR<0.05 in either 
